Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential

참고문헌 (155)

1. "The cause of cancer", JAMA, 325, pp.311~ (2021)
2. Martinez-Reyes, I., "Cancer metabolism: looking forward", Nat. Rev. Cancer, 21, pp.669~680 (2021)
3. Li, Z., "Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression", Cell Mol. Life Sci, 73, pp.377~392 (2016)
4. Callao, V., "Toxohormone-like factor from microorganisms with impaired respiration", Science, 134, pp.2041~2042 (1961)
5. Pavlova, N. N., "The emerging hallmarks of cancer metabolism", Cell Metab, 23, pp.27~47 (2016)
6. Hanahan, D., "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
7. Waddington, C. H., "Towards a theoretical biology", Nature, 218, pp.525~527 (1968)
8. Wu, C., "Genes, genetics, and epigenetics: a correspondence", Science, 293, pp.1103~1105 (2001)
9. Zhang, L., "Epigenetics in health and disease", Adv. Exp. Med. Biol, 1253, pp.3~55 (2020)
10. Kaliman, P., "Epigenetics and meditation", Curr. Opin. Psychol, 28, pp.76~80 (2019)
11. Papait, R., "Role of the epigenome in heart failure", Physiol. Rev, 100, pp.1753~1777 (2020)
12. Baylin, S. B., "Epigenetic determinants of cancer", Cold Spring Harb. Perspect. Biol, 8 (2016)[DOI]
13. Biswas, S., "Epigenetics in cancer : fundamentals and beyond", Pharmacol. Ther, 173, pp.118~134 (2017)
14. Flavahan, W. A., "Epigenetic plasticity and the hallmarks of cancer", Science, 357, pp.eaal2380~ (2017)
15. Jones, P. A., "Targeting the cancer epigenome for therapy", Nat. Rev. Genet, 17, pp.630~641 (2016)
16. Nepali, K., "Recent developments in epigenetic cancer therapeutics : clinical advancement and emerging trends", J. Biomed. Sci, 28, pp.27~ (2021)
17. Chen, W., "Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China : a comparative risk assessment", Lancet Glob. Health, 7, pp.e257~e269 (2019)
18. Sun, L., "Metabolic reprogramming and epigenetic modifications on the path to cancer", Protein Cell (2021)[DOI]
19. Thakur, C., "Connections between metabolism and epigenetics in cancers", Semin. Cancer Biol, 57, pp.52~58 (2019)
20. Warburg, O., "On the origin of cancer cells", Science, 123, pp.309~314 (1956)
21. Vaupel, P., "The Warburg effect : historical dogma versus current rationale", Adv. Exp. Med. Biol, 1269, pp.169~177 (2021)
22. Sun, L., "cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions", Cell Res, 25, pp.429~444 (2015)
23. Kierans, S. J., "Regulation of glycolysis by the hypoxia-inducible factor(HIF) : implications for cellular physiology", J. Physiol, 599, pp.23~37 (2021)
24. Al Tameemi, W., "Hypoxia-modified cancer cell metabolism", Front. Cell Dev. Biol, 7, pp.4~ (2019)
25. Nagao, A., "HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance", Int. J. Mol. Sci, 20 (2019)[DOI]
26. Bao, X., "The crosstalk between HIFs and mitochondrial dysfunctions in cancer development", Cell Death Dis, 12, pp.215~ (2021)
27. Vander Heiden, M. G., "Understanding the Warburg effect: the metabolic requirements of cell proliferation", Science, 324, pp.1029~1033 (2009)
28. Certo, M., "Lactate modulation of immune responses in inflammatory versus tumour microenvironments", Nat. Rev. Immunol, 21, pp.151~161 (2021)
29. Deng, F., "Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer", Theranostics, 9, pp.1001~1014 (2019)
30. Bal, C., "Positron emission tomography", computed tomography in thyroid cancer, 2022, pp.17, 265~283
31. Guglielmi, R., "18F FDG imaging - response criteria in tumors", Eur. J. Radiol, 147, pp.110054~ (2022)
32. Baier, D., "The anticancer ruthenium compound BOLD-100 targets glycolysis and generates a metabolic vulnerability towards glucose deprivation", Pharmaceutics, 14 (2022)[DOI]
33. Snaebjornsson, M. T., "Greasing the wheels of the cancer machine : the role of lipid metabolism in cancer", Cell Metab, 31, pp.62~76 (2020)
34. Bian, X., "Lipid metabolism and cancer", J. Exp. Med, 218 (2021)[DOI]
35. Gu, L., "The IKKbeta-USP30-ACLY axis controls lipogenesis and tumorigenesis", Hepatology, 73, pp.160~174 (2021)
36. Fhu, C. W., "Fatty acid synthase: an emerging target in cancer", Molecules, 25 (2020)[DOI]
37. Oatman, N., "Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer", Sci. Adv, 7 (2021)[DOI]
38. Ruiz de Gauna, M., "Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids", Hepatology (2022)[DOI]
39. Munir, R., "Too complex to fail? Targeting fatty acid metabolism for cancer therapy", Prog. Lipid Res, 85, pp.101143~ (2022)
40. Liu, W., "Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer", Nat. Commun, 12, pp.5103~ (2021)
41. King, R. J., "The cholesterol pathway : impact on immunity and cancer", Trends Immunol, 43, pp.78~92 (2022)
42. Lim, S. A., "Lipid signalling enforces functional specialization of Treg cells in tumours", Nature, 591, pp.306~311 (2021)
43. Elizabeth L. Lieu, "Amino acids in cancer", Experimental and Molecular Medicine, 52, pp.1~16 (2020), 생화학분자생물학회[DOI]
44. 유희찬, "Glutamine reliance in cell metabolism", Experimental and Molecular Medicine, 52, pp.1~21 (2020), 생화학분자생물학회[DOI]
45. Wei, Z., "Metabolism of amino acids in cancer", Front. Cell Dev. Biol, 8, pp.603837~ (2020)
46. Baksh, S. C., "Extracellular serine controls epidermal stem cell fate and tumour initiation", Nat. Cell Biol, 22, pp.779~790 (2020)
47. Muthusamy, T., "Serine restriction alters sphingolipid diversity to constrain tumour growth", Nature, 586, pp.790~795 (2020)
48. Tajan, M., "Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy", Nat. Commun, 12, pp.366~ (2021)
49. Hayes, J. D., "Oxidative stress in cancer", Cancer Cell, 38, pp.167~197 (2020)
50. Ying, M., "Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions", Redox Biol, 46, pp.102065~ (2021)
51. Ballestar, E., "Clinical value of DNA methylation markers in autoimmune rheumatic diseases", Nat. Rev. Rheumatol, 16, pp.514~524 (2020)
52. Navas-Acien, A., "Blood DNA methylation and incident coronary heart disease : evidence from the strong heart study", JAMA Cardiol, 6, pp.1237~1246 (2021)
53. Nishiyama, A., "Navigating the DNA methylation landscape of cancer", Trends Genet, 37, pp.1012~1027 (2021)
54. Xu, Q., "Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development", Proc. Natl Acad. Sci. USA, 119 (2022)[DOI]
55. Wong, K. K., "DNMT1 : A key drug target in triple-negative breast cancer", Semin Cancer Biol, 72, pp.198~213 (2021)
56. Wu, D., "Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer", Nature, 559, pp.637~641 (2018)
57. Pulikkottil, A. J., "TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways", Leukemia, 36, pp.416~425 (2022)
58. Le, X., "DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative", ER stress-mediated apoptosis and pyroptosis, 2020, pp.10, 9495~9511
59. Feng, J., "Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1alpha stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment", Oncogene, 38, pp.103~119 (2019)
60. Zhong, X., "Downregulation of SLC27A6 by DNA hypermethylation promotes proliferation but suppresses metastasis of nasopharyngeal carcinoma through modulating lipid metabolism", Front. Oncol, 11, pp.780410~ (2021)
61. Chen, Y., "The role of histone methylation in the development of digestive cancers : a potential direction for cancer management", Signal Transduct. Target. Ther, 5, pp.143~ (2020)
62. Tran, T. Q., "Molecular pathways : metabolic control of histone methylation and gene expression in cancer", Clin. Cancer Res, 23, pp.4004~4009 (2017)
63. Yuan, G., "Elevated NSD3 histone methylation activity drives squamous cell lung cancer", Nature, 590, pp.504~508 (2021)
64. Koutsioumpa, M., "Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming", Gut, 68, pp.1271~1286 (2019)
65. Alam, H., "KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer", Cancer Cell, 37, pp.599~617 (2020)
66. Maitituoheti, M., "Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma", Cell Rep, 33, pp.108293~ (2020)
67. Wu, J., "Histone methyltransferase SETD1A interacts with HIF1alpha to enhance glycolysis and promote cancer progression in gastric cancer", Mol. Oncol, 14, pp.1397~1409 (2020)
68. Wan, W., "Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1alpha", Oncogene, 36, pp.3868~3877 (2017)
69. Zhang, Z. G., "KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming", Exp. Cell Res, 379, pp.182~190 (2019)
70. Matsushita, H., "In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia", J. Exp. Med, 203, pp.821~828 (2006)
71. An, X., "Histone deacetylase inhibitor trichostatin a suppresses cell proliferation and induces apoptosis by regulating the PI3K", AKT signalling pathway in gastric cancer cells, 2020, pp.20, 2114~2124
72. Cai, L. Y., "Targeting p300", CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism, 2021, pp.81, 860~872
73. Jiang, X., "BPIFB1 inhibits vasculogenic mimicry via downregulation of GLUT1-mediated H3K27 acetylation in nasopharyngeal carcinoma", Oncogene, 41, pp.233~245 (2022)
74. Chen, C. L., "Arginine is an epigenetic regulator targeting TEAD4 to modulate OXPHOS in prostate cancer cells", Nat. Commun, 12, pp.2398~ (2021)
75. Rabinowitz, J. D., "Lactate : the ugly duckling of energy metabolism", Nat. Metab, 2, pp.566~571 (2020)
76. Brown, T. P., "Lactate", GPR81 signaling and proton motive force in cancer : role in angiogenesis, immune escape, nutrition, and Warburg phenomenon, 2020, pp.206, 107451~
77. Daw, C. C., "Lactate elicits ER-mitochondrial Mg(2+) dynamics to integrate", Cellular Metabolism. Cell, 183, pp.474~489 (2020)
78. Lundo, K., "Why Warburg works:lactate controls immune evasion through GPR81", Cell Metab, 31, pp.666~668 (2020)
79. Zhang, D., "Metabolic regulation of gene expression by histone lactylation", Nature, 574, pp.575~580 (2019)
80. Yu, J., "Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma", Genome Biol, 22, pp.85~ (2021)
81. Xiong, J., "Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells", Mol. Cell (2022)[DOI]
82. Jiang, J., "Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer", Front. Oncol, 11, pp.647559~ (2021)
83. Vinasco, K., "Microbial carcinogenesis : lactic acid bacteria in gastric cancer", Biochim. Biophys. Acta Rev. Cancer, 1872, pp.188309~ (2019)
84. Bhagat, T. D., "Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts", Elife, 8 (2019)[DOI]
85. Yang, Z., "Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma", Nat. Metab (2023)[DOI]
86. Kebede, A. F., "Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest", FEBS J, 282, pp.1658~1674 (2015)
87. Liu, H., "Rab26 suppresses migration and invasion of breast cancer cells through mediating autophagic degradation of phosphorylated Src", Cell Death Dis, 12, pp.284~ (2021)
88. Zhu, D., "Histone citrullination : a new target for tumors", Mol. Cancer, 20, pp.90~ (2021)
89. Thomas, D., "Altered glycosylation in cancer:a promising target for biomarkers and therapeutics", Biochim. Biophys. Acta (BBA)Rev. Cancer, 1875 (2021)[DOI]
90. Sun, L., "Targeting glycosylated PD-1 induces potent antitumor immunity", Cancer Res, 80, pp.2298~2310 (2020)
91. Dang, F., "Ubiquitin signaling in cell cycle control and tumorigenesis", Cell Death Differ, 28, pp.427~438 (2021)
92. Li, X., "CUL3(cullin 3)-mediated ubiquitination and degradation of BECN1(beclin 1)inhibit autophagy and promote tumor progression", Autophagy, 17, pp.4323~4340 (2021)
93. Liu, J., "UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination", Nat. Cell Biol, 22, pp.1056~1063 (2020)
94. Clapier, C. R., "The biology of chromatin remodeling complexes", Annu. Rev. Biochem, 78, pp.273~304 (2009)
95. Kadoch, C., "Diverse compositions and functions of chromatin remodeling machines in cancer", Sci. Transl. Med, 11 (2019)[DOI]
96. Mittal, P., "The SWI", SNF complex in cancer - biology, biomarkers and therapy, 2020, pp.17, 435~448
97. Saqcena, M., "SWI", SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies, 2021, pp.11, 1158~1175
98. Ding, H., "Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation", Cancer Cell Int, 21, pp.655~ (2021)
99. Lin, H., "Loss of SNF5 expression correlates with poor patient survival in melanoma", Clin. Cancer Res, 15, pp.6404~6411 (2009)
100. Wu, S., "Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma", Nat. Cancer, 2, pp.189~200 (2021)
101. Ogiwara, H., "Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers", Cancer Cell, 35, pp.177~190 (2019)
102. Wu, Q., "The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation", Oncotarget, 7, pp.38270~38281 (2016)
103. Li, Y., "The emerging role of ISWI chromatin remodeling complexes in cancer", J. Exp. Clin. Cancer Res, 40, pp.346~ (2021)
104. Zikmund, T., "Loss of ISWI ATPase SMARCA5(SNF2H)in acute myeloid leukemia cells inhibits proliferation and chromatid cohesion", Int. J. Mol. Sci, 21 (2020)[DOI]
105. Zhou, B., "INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma", Genes Dev, 30, pp.1440~1453 (2016)
106. Prendergast, L., "Resolution of R-loops by INO80 promotes DNA replication and maintains cancer cell proliferation and viability", Nat. Commun, 11, pp.4534~ (2020)
107. Zhou, B., "Translation of noncoding RNAs and cancer", Cancer Lett, 497, pp.89~99 (2021)
108. Haugen, O. P., "Transcriptomic and functional studies reveal miR-431-5p as a tumour suppressor in pancreatic ductal adenocarcinoma cells", Gene, 822, pp.146346~ (2022)
109. Chen, L., "MiR-601 promotes cell proliferation of human glioblastoma cells by suppressing TINP1 expression", Altern. Ther. Health Med, 28, pp.102~108 (2022)
110. Kim, T., "MicroRNA and ER stress in cancer", Semin. Cancer Biol, 75, pp.3~14 (2021)
111. Orso, F., "Role of miRNAs in tumor and endothelial cell interactions during tumor progression", Semin. Cancer Biol, 60, pp.214~224 (2020)
112. Xiao, C., "MicroRNA control of B cell tolerance, autoimmunity and cancer", Semin. Cancer Biol, 64, pp.102~107 (2020)
113. Hou, Y., "YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect", Cell Death Differ, 28, pp.3105~3124 (2021)
114. Zou, J., "LIX1-like protein promotes liver cancer progression via miR-21-3pmediated inhibition of fructose-1, 6-bisphosphatase", Acta Pharm. Sin. B, 11, pp.1578~1591 (2021)
115. Cannistraci, A., "MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer", Oncogene, 41, pp.1445~1455 (2022)
116. Liu, Y., "MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming", J. Hematol. Oncol, 13, pp.12~ (2020)
117. Yang, L., "Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines", Cell Death Differ, 28, pp.2708~2727 (2021)
118. Fong, M. Y., "Cancer-secreted miRNAs regulate amino-acid-induced mTORC1 signaling and fibroblast protein synthesis", EMBO Rep, 22, pp.e51239~ (2021)
119. Yang, J., "Glycolysis reprogramming in cancer-associated fibroblasts promotes the growth of oral cancer through the lncRNA H19", miR-675-5p, Int. J. Oral Sci, pp.2021, 13[DOI]
120. Hong, J., "F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer", Gut, 70, pp.2123~2137 (2021)
121. Rupaimoole, R., "Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis", Cell Rep, 13, pp.2395~2402 (2015)
122. Huang, X., "LINC00842 inactivates transcription co-regulator PGC-1alpha to promote pancreatic cancer malignancy through metabolic remodelling", Nat. Commun, 12, pp.3830~ (2021)
123. Liu, S., "A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties", J. Hematol. Oncol, 14, pp.178~ (2021)
124. Zhang, G., "Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis", Oncogene, 40, pp.2936~2951 (2021)
125. Ge, Q., "Micropeptide ASAP encoded by LINC00467 promotes colorectal cancer progression by directly modulating ATP synthase activity", J. Clin. Invest, 131 (2021)[DOI]
126. Sun, L., "Lnc-NA inhibits proliferation and metastasis in endometrioid endometrial carcinoma through regulation of NR4A1", J. Cell Mol. Med, 23, pp.4699~4710 (2019)
127. Kristensen, L. S., "The biogenesis, biology and characterization of circular RNAs", Nat. Rev. Genet, 20, pp.675~691 (2019)
128. Pamudurti, N. R., "Translation of CircRNAs", Mol. Cell, 66, pp.9~21 (2017)
129. Yu, T., "CircRNAs in cancer metabolism : a review", J. Hematol. Oncol, 12, pp.90~ (2019)
130. Li, J., "CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma", Cancer Res, 82, pp.1055~1069 (2022)
131. Li, Q., "Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p", PKM2 axis under hypoxic stress, 2019, pp.70, 1298~1316
132. Liu, P., "The FUS", circEZH2, feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition, pp.Mol. Cancer, 2022[DOI]
133. Shen, S., "CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc", Mol. Cancer, 19, pp.151~ (2020)
134. Dang, R. Y., "Circular RNA hsa_circ_0010729 regulates vascular endothelial cell proliferation and apoptosis by targeting the miR-186", HIF-1alpha axis, 2017, pp.490, 104~110
135. Chen, L. Y., "The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p", 4EBP-1 mediated capindependent HIF-1alpha translation, 2020, pp.19, 164~
136. Mo, Y., "Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2", Mol. Cancer, 20, pp.112~ (2021)
137. Li, Q., "CircACC1 regulates assembly and activation of AMPK complex under metabolic stress", Cell Metab, 30, pp.157~173 (2019)
138. Pan, Z., "A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer", Mol. Cancer, 19, pp.71~ (2020)
139. Zhang, Z., "Co-targeting Plk1 and DNMT3a in advanced prostate cancer", Adv. Sci, 8, pp.e2101458~ (2021)
140. Tsimberidou, A. M., "Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors", Clin. Cancer Res, 27, pp.3584~3594 (2021)
141. Hogg, S. J., "Targeting the epigenetic regulation of antitumour immunity", Nat. Rev. Drug Discov, 19, pp.776~800 (2020)
142. Xia, L., "The cancer metabolic reprogramming and immune response", Mol. Cancer, 20, pp.28~ (2021)
143. Dai, E., "Epigenetic modulation of antitumor immunity for improved cancer immunotherapy", Mol. Cancer, 20, pp.171~ (2021)
144. Sheng, W., "LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade", Cell, 174, pp.549~563 (2018)
145. Topper, M. J., "Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer", Cell, 171, pp.1284~1300 (2017)
146. Akbari, B., "Epigenetic strategies to boost CAR T cell therapy", Mol. Ther, 29, pp.2640~2659 (2021)
147. DeFrancesco, L., "Chroma Medicine and Tune Therapeutics: two companies take up epigenome editing", Nat. Biotechnol (2022)[DOI]
148. Hilton, I. B., "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers", Nat. Biotechnol, 33, pp.510~517 (2015)
149. Ansari, I., "CRISPR", Cas mediated epigenome editing for cancer therapy, 2022, pp.83, 570~583
150. Almassalha, L. M., "Macrogenomic engineering via modulation of the scaling of chromatin packing density", Nat. Biomed. Eng, 1, pp.902~913 (2017)
151. Ehteda, A., "Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG", Cell Rep, 35, pp.108994~ (2021)
152. Ge, T., "Crosstalk between metabolic reprogramming and epigenetics in cancer : updates on mechanisms and therapeutic opportunities", Cancer Commun, 42, pp.1049~1082 (2022)
153. Zhang, Y., "Transcription regulation by histone methylation : interplay between different covalent modifications of the core histone tails", Genes Dev, 15, pp.2343~2360 (2001)
154. Zhao, Y., "The crosstalk between m(6)A RNA methylation and other epigenetic regulators : a novel perspective in epigenetic remodeling", Theranostics, 11, pp.4549~4566 (2021)
155. D’Alessio, A. C., "Epigenetic tete-a-tete : the bilateral relationship between chromatin modifications and DNA methylation", Biochem. Cell Biol, 84, pp.463~476 (2006)

관련 논문AI추천